SCHEMBL24256423

SCHEMBL24256423

CC(C)Cc1nc2sc3c(NCCN4CCOCC4)ncnc3c2c2c1CCC2

nearest known ligand 0.79

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 15/20 0.79
PDE4A P27815 7/20 0.79
PDE4D Q08499 7/20 0.79
KDM4E B2RXH2 3/20 0.72
ALDH1A1 P00352 3/20 0.72
LMNA P02545 2/20 0.72
ADRB2 P07550 1/20 0.72
GAA P10253 1/20 0.72
HPGD P15428 1/20 0.72
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
POLB P06746 1/20 0.59
HTT P42858 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
RAD52 P43351 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256420 0.89 KDM4E (0.73) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL4046613 0.89 PDE4B (1.00) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL24256385 0.88 KDM4E (0.75) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL24256417 0.87 KDM4E (0.71) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL5322840 0.85 PDE4B (0.91) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL24256416 0.84 KDM4E (0.66) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL24256377 0.83 KDM4E (0.67) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL5012378 0.78 PDE4B (0.93) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL5011359 0.77 PDE4B (1.00) PDE4BPDE4APDE4DKDM4EALDH1A1
SCHEMBL4047975 0.76 PDE4B (0.78) PDE4BPDE4APDE4DKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 PDE4B 3239/4885PDE4A 2729/4885PDE4D 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.